The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 225.00
Bid: 220.00
Ask: 230.00
Change: 10.00 (4.65%)
Spread: 10.00 (4.545%)
Open: 215.00
High: 234.00
Low: 225.00
Prev. Close: 215.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Manufacturer Ends Traumakine Agreement With Faron Pharmaceuticals

Wed, 02nd Oct 2019 13:13

(Alliance News) - Faron Pharmaceuticals Oy on Wednesday said Rentschler Biopharma SE has terminated its agreement to manufacture the active ingredient in Traumakine.

Shares in Faron were down 4.5% at 96.00 pence in London in midday trading.

Traumakine is being developed by Faron as a treatment for acute respiratory distress syndrome, where a patient's lungs become very inflamed as a result of a injury or an infection. The syndrome causes difficulty breaching and those who develop it are typically admitted to intensive care and put on a ventilator.

Drug developer Faron announced in its half-year results on September 23 that the process being used to make Traumakine's active ingredient would need "significant upgrading" for Faron to ever obtain a biologics license application in the US or marketing authorisation application in the EU.

Faron said it understood Rentschler's decision to terminate the agreement relates to the need for upgraded manufacturing to make Traumakine's active ingredient.

The firm said it is "exploring various options" to make the active ingredient in the future and the termination will not hurt its "clinical advice process" with the Us Food & Drug Administration or European Medicines Agency and is focused "on the structure of the next Traumakine clinical study".

Within its interim results announcement, Faron also disclosed that it had closed its phase 2 Inforaaa study of Traumakine's effect on mortality for patients with surgically operated Ruptured Abdominal Aorta Aneurysm.

While the patients demonstrated a good response to the drug, the high use of corticosteroids among study patients hindered implementation of the study's protocol.

Previous studies have found that taking corticosteroids reduces the action of Traumakine's active ingredient, but such steroids are often the standard of treatment for the patient population Faron is studying. The firm is thus seeking advice on how to structure a trial to account for this problem.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
25 Aug 2021 11:43

Faron doses first patient in Covid-19 treatment trial

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals announced on Wednesday that the first patient has been dosed in the phase 2 and 3 'HIBISCUS' trial, assessing 'Traumakine', or intravenous interferon beta-1a, as a first-line treatment for hospitalised Covid-19 patients.

Read more
25 Aug 2021 11:38

IN BRIEF: Faron Pharmaceuticals begins study of new Covid treatment

IN BRIEF: Faron Pharmaceuticals begins study of new Covid treatment

Read more
19 Aug 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
14 Jun 2021 10:33

Faron Pharmaceuticals granted US patent for cancer immunotherapy drug

Faron Pharmaceuticals granted US patent for cancer immunotherapy drug

Read more
3 Jun 2021 19:20

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

Read more
3 Jun 2021 14:47

New research supports mode of action in Faron's 'MATINS' study

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced the publication of research supporting the immunotherapeutic blockade of 'Clever-1' to activate anti-tumour immune responses in advanced cancer patients on Thursday.

Read more
17 May 2021 17:49

TRADING UPDATES: Wey takeover edges closer; Acorn in strategy switch

TRADING UPDATES: Wey takeover edges closer; Acorn in strategy switch

Read more
17 May 2021 10:13

Faron Pharmaceuticals reports 'promising' data from drug study

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced "promising" new data from its ongoing bexmarilimab 'MATINS' study on Monday, reporting combined headline data from 141 evaluable patients enrolled in the completed first part and the ongoing second part of the study.

Read more
14 May 2021 12:29

Faron Pharmaceuticals gets US rights to patent related to Traumakine

Faron Pharmaceuticals gets US rights to patent related to Traumakine

Read more
14 May 2021 11:18

Faron Pharmaceuticals signs US sublicence agreement

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has signed a sublicence agreement for the rights to United States patent US9,376,478, it announced on Friday, which currently extends to 2033.

Read more
23 Apr 2021 15:43

EXECUTIVE CHANGES: Universe Group hires CFO as new CEO also joins

EXECUTIVE CHANGES: Universe Group hires CFO as new CEO also joins

Read more
16 Apr 2021 14:54

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
25 Mar 2021 14:49

TRADING UPDATES: Safestyle in strong start to 2021; Tandem ups payout

TRADING UPDATES: Safestyle in strong start to 2021; Tandem ups payout

Read more
22 Mar 2021 11:22

AIM WINNERS & LOSERS: Futura Medical shares rise on US FDA agreement

AIM WINNERS & LOSERS: Futura Medical shares rise on US FDA agreement

Read more
22 Mar 2021 09:32

Faron Pharmaceuticals shares boosted by positive data on cancer drug

Faron Pharmaceuticals shares boosted by positive data on cancer drug

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.